549-56-4C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12.O=S(=O)(O)OAKYHKWQPZHDOBW-DSXUQNDKSA-NSee also: Quinine (has active moiety); Quinine Sulfate (annotation moved to) ... View More ...
549-56-4、6119-70-6、7778-93-0、804-63-7Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Danger
H315 (98.5%): Causes skin irritation [Warning Skin corrosion/irritation]
P233, P260, P261, P264, P264+P265, P271, P272, P280, P284, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P333+P317, P337+P317, P342+P316, P362+P364, P403, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 131 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Warning
H302: Harmful if swallowed [Warning Acute toxicity, oral]
Chemical: Cinchonan-9-ol, 6'-methoxy-, (8.alpha.,9R)-, sulfate(2:1) (salt), dihydrate
Chemical: Cinchonan-9-ol, 6'-methoxy-, (8.alpha.,9R)-, sulfate (1:1) (salt)
REACH registered substance: Quinine hydrogen sulphate (EC: 208-970-9)
Cinchonan-9-ol, 6'-methoxy-, (8.alpha.,9R)-, sulfate (1:1) (salt): Does not have an individual approval but may be used under an appropriate group standard
IMAP assessments - Quinine and its salts: Human health tier II assessment
IMAP assessments - Quinine and its salts: Human health tier II assessment
An irritant; Harmful by ingestion; The anhydrous form has produced effects in experimental animals including muscle weakness, interstitial nephritis, tinnitus, hepatitis, cirrhosis, acute pulmonary edema, visual field changes, cardiomyopathy, and reproductive effects; [Alfa Aesar MSDS]
Skin Irrit. 2 (98.5%)
Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585)
A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358)
A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS.
UsesQuinine Bisulfate (cas# 549-56-4) is a compound useful in organic synthesis.
UsesAntiprotozoal (malaria).
CHEMBL1201100、CHEMBL2146083Acute toxicity - category 4
Acute toxicity - category 4